|
Aradigm's Scientific Advisory Board is a highly regarded team of scientific experts who help the Company with strategic input into the development of treatments for severe respiratory disease, hormonal and metabolic disorders, and in pharmaceutical development and pulmonary drug delivery in general. The group assists the company on a variety of issues related to potential product applications, product development paths and clinical testing.
Peter R. Byron Ph.D.
Medical College of Virginia, Virginia Commonwealth University.
Area of expertise: Aerosol Science/ Pharmaceutics
Peter S. Creticos M.D.
The Johns Hopkins University School of Medicine
Area of expertise: Allergy/Immunology/Asthma
Stephen J. Farr Ph.D.
Zogenix, Inc.
Area of expertise: Pulmonary Delivery/Pharmaceutics
Michael Konstad M.D.
Rainbow Babies and Children's Hospital
Area of expertise: Pulmonary Disease/Cystic Fibrosis
Babatunde A. Otulana M.D.
Aradigm Corp, Senior Vice President, Development, Chief Medical Officer
Area of expertise:
Adam Wanner M.D.
University of Miami
Area of expertise: Chronic Obstructive Pulmonary Disease (COPD)
Martin Wasserman Ph.D.
Roche, AtheroGenics (retired)
Area of expertise: Asthma
In addition to this Scientific Advisory Board, the company also engages other scientific and medical experts to assist on issues specific to particular indications and programs.
|
Scientific Advisory Board
